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Abstract
Background:  Information regarding hepatitis C virus genotypes and subtypes circulating in
Pakistan and various risk factors for their transmission are not known well. The specific objective
of this study was to find out the frequency of various HCV genotypes present in well-characterized
Pakistani HCV isolates and their possible routes of transmission.
Methods: A total of 3351 serum samples were tested by type-specific genotyping assay. Out of
3351 HCV RNA positive patients, 2039 were males and 1312 were females. As regard as genotyped
samples, 2165 belonged to Punjab region, 823 belonged to N.W.F.P., 239 to Sindh and 124 patients
were from Balochistan.
Results: Out of the total 3351 tested serum samples, type-specific PCR fragments were observed
in 3150 (94.00%) serum samples. The distribution of genotypes of the typeable samples as
determined by this assay, was as follows: 1664 (49.05%) genotype 3a; 592 (17.66%) genotype 3b;
280 (8.35%) genotype 1a; 252 (7.52%) genotype 2a; 101 (3.01%) genotype 1b; 50 (1.49%) with
genotype 4; 25 (0.75%) with 3c; 27 (0.80%) genotype 2b; 6 (0.18%) with subtype 5a; 5 (0.15%)
genotype 1c; 4 (0.12%) with subtype 6a; 3 (0.09%) genotype 2c; and 161 (4.80%) patients were
infected with mixed infection. Two hundred and one (5.99%) serum samples were found
untypeable by the present genotyping system. More than 86% and 72% patients with genotypes 3a
and 3b respectively had received multiple injections in past. For genotypes 1a and 1b the route of
transmission was major/minor surgery along with unknown reasons. Majority of the cases with type
2a, 2b and indeterminate genotypes were sporadic. Mixed infections were common in thalassaemic
patients.
Conclusion: The most common HCV genotype in Pakistan is type 3a. Regional difference in
genotypes was observed only in Balochistan province of Pakistan. More than 70% of the cases were
acquired in hospitals through reuse of needles/syringes and major/minor surgery that is very
common in this country.
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Background
Hepatitis C virus (HCV) infection is one of the most
important Flaviviridae infections with significant clinical
problems throughout the world in humans and it is
responsible for the second most common cause of viral
hepatitis [1]. To date at least six major genotypes of HCV,
each having multiple subtypes, have been identified
worldwide [2]. The different genotypes are relevant to epi-
demiology, vaccine development, and clinical manage-
ment of chronic HCV infection [3]. Furthermore, the HCV
genotype is the strongest predictive parameter for sus-
tained virological response [4]. This clinical relevance of
HCV genotyping attracted attention from studies that
reported an influence of HCV genotypes on the clinical
course of disease and response to interferon therapy, as
patients with different HCV genotypes respond differently
to alpha interferon [5]. Firm evidence has been estab-
lished that patients with type 2 and type 3 HCV infections
are more likely to have a sustained response to therapy
than patients with type 1 HCV infections [6]. Rates of sus-
tained virological response to combination therapy in
patients infected with HCV-2/3 and HCV-1 genotypes are
65% and 30%, respectively [7,8]. Therefore the patient
genotype should be taken into consideration when pre-
scribing interferon standard therapy.
HCV genotypes 1, 2, and 3 appear to have a worldwide
distribution and their relative prevalence varies from one
geographic area to another. HCV subtypes 1a and 1b are
the most common genotypes in the United States [4].
These subtypes also are predominant in Europe [9-11].
The predominant subtype reported from Japan is subtype
1b that is responsible for up to 73% of cases of HCV infec-
tion [12]. HCV subtypes 2a and 2b are relatively common
in North America, Europe, and Japan and subtype 2c is
found commonly in northern Italy. HCV genotype 4
appears to be prevalent in North Africa and the Middle
East [13,14], and genotypes 5 and 6 seem to be confined
to South Africa and Hong Kong, respectively [15,16]. HCV
genotypes 7, 8, and 9 have been identified only in Viet-
namese patients [17], and genotypes 10 and 11 were iden-
tified in patients from Indonesia [18]. There has been
disagreement about the number of genotypes into which
HCV isolates should be classified. Investigators have pro-
posed that genotypes 7 through 11 should be regarded as
variants of the same group and classified as a single geno-
type, type 6 [19,20].
From Pakistan few studies are available on the distribu-
tion of various hepatitis C virus genotypes based on small
sample sizes [13,21,22]. No study is available on geo-
graphic variation in the prevalence of various HCV geno-
types and various routes of transmission for different
genotypes from Pakistan. Therefore, this study was initi-
ated to determine the frequency distribution of various
HCV genotypes and subtypes present in different geo-
graphical regions of Pakistan and to determine various
risk factors for its transmission.
Methods
Source of Clinical Samples
All the serum samples were received along with specifi-
cally designed data sheets at Division of Molecular Virol-
ogy & Molecular Diagnostics, Centre for Applied
Molecular Biology, Lahore from 121 tertiary collection
centers situated in different cities/towns of all the four
provinces of Pakistan such as North West Frontier Prov-
ince (NWFP), Punjab, Sindh and Balochistan for the
detection of HCV during the course of this study. Pakistan
is situated in the western part of the Indian subcontinent,
with Afghanistan and Iran on the west, India on the east,
and the Arabian Sea on the south. Pakistan is the sixth
most populous country in the world. Pakistan is a federa-
tion of four provinces (described above), a capital terri-
tory and federally administered tribal areas. The total land
area is estimated at 803,940 square kilometers. Estimated
(2007) population of the country is 169,270,617. Serum
samples from chronic HCV carriers showing HCV RNA
positivity with all the required information representing
the four provinces of Pakistan were included in the study.
The N.W.F.P was represented by cities/towns of Peshawar,
Mardan, Malakand, Dir, Swat, DI Khan and Bunnu
(number of isolates [n] = 823); the Punjab was repre-
sented by Lahore, Gujranwala, Mandi Bahauddin, Mul-
tan, Sarghoda, Jehlum, Sialkot, Rawalpindi, Rahim Yar
Khan and Faisalabad (n = 2165); the Sindh was repre-
sented by Karachi, Hydarabad, Khair Pur, Nawab Shah,
Dadu and Mirpur Khas (n = 239); and Balochistan was
represented by Quetta, Ziarat and Sibbi (n = 124). The iso-
lates from NWFP, Punjab, Sindh, or Balochistan were des-
ignated as NP, PP, SP, or BP, respectively, to identify the
origin of the samples. A written informed consent was
taken from patients and the data sheet contained demo-
graphic of patients, possible route of transmission, area,
and estimated time of infection and complete address of
the patients with telephone numbers. The study was
approved by the ethics committee of the Institute.
HCV RNA Detection and quantitative PCR
Nested reverse transcriptase (RT) PCR was carried out for
the qualitative detection of HCV RNA using primers cor-
responding to 5'NCR primers as described previously
[23]. Briefly, RNA was extracted from 100 μl serum sam-
ples using Gentra (Puregene, Minneapolis, MN 55441
USA) RNA isolation kit according to the protocol
described in the kit. Moloney murine leukemia virus
(MMLV) reverse transcriptase enzyme (RTEs) (Invitrogen,
Corp., California USA) was used for reverse transcription
of HCV 5'NCR with outer antisense primer. First-round
and nested PCRs were carried out with Taq polymeraseBMC Infectious Diseases 2008, 8:69 http://www.biomedcentral.com/1471-2334/8/69
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(Invitrogen, Corp., California USA), and the specific HCV
PCR bands were visualized on 2% agarose gel. Quantifica-
tion of HCV RNA was performed for PCR positive sera
with SmartCycler II Real-time PCR (Cepheid, Sunnyvale,
Calif. USA). The SmartCycler II system is a PCR system by
which amplification and detection are accomplished con-
currently with TaqMan technology (Applied Biosystems,
Foster City, Calif) using fluorescent probes to detect
amplification after each replicating cycle. This assay has
lower and upper detection limits of 5.0 × 102 and 5.0 ×
107 IU/mL, respectively. Specimens yielding values above
the upper limit were routinely diluted 100-fold and
retested and obtained values were multiplied by this dilu-
tion factor to obtain the actual HCV RNA concentration in
international units per mL.
HCV Genotyping
HCV genotyping was carried out using type-specific HCV
genotyping method as described previously in detail [24].
Briefly, about 50 ng of HCV RNA was reverse transcribed
to cDNA using 100 U of M-MLV RTEs at 37°C for 50 min-
utes. Two μl of synthesized cDNA was used for PCR
amplification of 470-bp region from HCV 5'NCR plus
core region by first round PCR amplification. As there
were 12 different HCV types that we tried to detect, so the
type-specific primers were divided into two groups on the
basis of differences in the sizes of the different bands, so
that no genotype-specific bands are of same size in the
same group on agarose gel. Therefore, two second-round
PCRs were performed for each first round PCR sample,
one with primer mix A and the other with mix B in a vol-
ume of 20 μl with nested PCR primers. Mix-A contained
primers for genotypes 1a, 1b, 1c, 3a, 3c and 4 and Mix-B
included the 2a, 2c, 3b, 5a, and 6a primers. The second
round PCR product was electrophoresed on a 2% agarose
gel to separate type-specific fragment. Stained the gel with
ethidium bromide and evaluated under UV transillumi-
nator. A 100-bp DNA ladder (Invitrogen, Corp., Califor-
nia, USA) was run in each gel as DNA size marker and the
HCV genotype for each sample was determined by identi-
fying the HCV genotype-specific PCR band.
Sequencing of 5'NCR
The 5'UTR region of all the 201 untypable isolates were
sequenced in both directions and sequences that were
obtained for the first time were submitted to GenBank
data base. The Accession Numbers provided for our nucle-
otide sequences by the GeneBank are from EF173931 to
EF174030.
Statistical analysis
The data was analyzed and the summary statistic was car-
ried out by a statistical package, SPSS version 10.0 for win-
dow. The results for all variables were given in the form of
rates (%). Chi Square and Fisher's Exact tests were used for
categorical variables that measured association among
categorical variables. All data are presented as mean val-
ues or number of patients. P-values less than 0.05 were
considered significant.
Results
Demographic of patients
Figure 1 shows the study enrolment of patients and exclu-
sion criteria. During the course of this study, total of 5723
anti-HCV positive sera were received from all the four
provinces of the country. Out of these 3735 samples were
found positive by HCV qualitative PCR. After HCV RNA
quantification, 384 samples were excluded from the study
due to low viral load (<500 IU/ml) and 3351 serum sam-
ples with viral load >500 IU/ml were tested by type-spe-
cific genotyping assay. Out of 3351 patients, 2039 were
males and 1312 were females. Total of 2165 genotyped
patients belonged to Punjab region, 823 patients to
N.W.F.P., 239 to Sindh and 124 patients were from Balo-
chistan. All serum samples tested were HCV-RNA positive
with enough viral load and could thus be genotyped by
genotype-specific PCR assay.
Distribution of HCV genotypes in the study population
Table 1 shows the distribution of HCV genotypes in the
study population. Out of the total 3351 tested serum sam-
ples, type-specific PCR fragments were observed in 3150
(94.00%) serum samples. The distribution of genotypes
of the typeable samples as determined by this assay, was
as follows: 1664 (49.05%) were genotype 3a; 592
(17.66%) genotype 3b; 280 (8.35%) genotype 1a; 252
(7.52%) genotype 2a; 101 (3.01%) genotype 1b; 50
(1.49%) genotype 4; 25 (0.75%) 3c; 27 (0.80%) genotype
2b; 6 (0.18%) subtype 5a; 5 (0.15%) genotype 1c; 4
(0.12%) subtype 6a; 3 (0.09%) genotype 2c; and 161
(4.80%) patients were infected with mixed infection. Two
hundred and one (5.99%) serum samples were found
untypable by the present genotyping system. Six geno-
types i.e. 1c, 2c, 3c, 4, 5a and 6a were isolated for the first
time from Pakistan in the course of the present study. The
5'UTR region of all the 201 untypable isolates were
sequenced in both directions and sequences that were
obtained for the first time were submitted to GenBank
data base. The Accession Numbers provided for our nucle-
otide sequences by the GeneBank are from EF173931 to
EF174030.
HCV genotypes in male and female patients
The distributions of HCV genotypes were similar in male
and female patients.
Frequency of HCV genotypes in different geographical 
regions
Frequency of HCV genotypes were examined by individ-
ual Provinces shown in table 2. Among the genotypesBMC Infectious Diseases 2008, 8:69 http://www.biomedcentral.com/1471-2334/8/69
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determined from 2165 Punjabi patients, 7.94% (n = 172)
belonged to genotype 1a, 2.72% (n = 59) genotype 1b,
0.18% (n = 4) genotype 1c, 6.46% (n = 140) genotype 2a,
0.69% (n = 18) genotype 2b, 0.09% (n = 2) genotype 2c,
52.10% (n = 1128) genotype 3a, 16.53% (n = 358) geno-
type 3b, 0.64% (n = 14) genotype 3c, 1.15% (n = 25) gen-
otype 4, 0.23% (n  = 5) genotype 5a, 0.05% (n  = 1)
genotype 6a, and 4.34% (n = 101) were dual genotypes.
From NWFP 823 cases were grouped after genotyping as
follows: subtype 1a in 54 (6.56%); 1b in 21 (2.55%); 2a
in 63 (7.65%); 2b in 7 (0.85%); 2c in 1 (0.12%); 3a in
397 (48.23%); 3b in 157 (19.07%); 3c in 7 (0.85%), gen-
otype 4 in 19 (2.30%), 5a in 1 patient (0.12%); 6a in 3
(0.36%); mixed in 42 (5.10%) and untypeable in 51
(6.19%) patients. In Sindh genotype 3a was predominant
in being found in 95 (39.74%) of samples followed by 3b
Study enrollment of patients Figure 1
Study enrollment of patients. For study enrollments the patients were required to have chronic HCV with positive anti-
HCV ELISA. The patients were also required to have detectable HCV RNA by qualitative RT-PCR and viral load >500 IU/ml 
and belonged to any of the four provinces of Pakistan
 
3735 sera were further tested by Real-time PCR 
for HCV RNA quantification 
384 sera were excluded from the study 
due to low viral load (<500 IU/ml) that 
may not be enough to be genotyped 
1988 sera were excluded from the study 
because they were negative by HCV 
RNA PCR and failed to meet inclusion 
criteria  
Total 5723 anti-HCV positive sera samples of 
patients with chronic HCV were tested by HCV 
Qualitative PCR 
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(26.35%), 2a (9.62%), 1a (9.2%), 1b (3.76%), 3c
(1.25%) and genotype 4 (0.41%). Twelve (5.02%) mixed
genotypes were also isolated from this area and 10
(4.18%) samples were found untypeable. Among patients
from Balochistan, genotypes 1a (25.8%) was the most
prevalent followed by 2a (20.96%), 3a (19.35%), and 3b
(11.29%); 1b (9.67%); 2b (10.8%); genotype 4 (4.03%);
1c (0.80%) and 3c (0.80%). Six (4.83%) of the isolates
were found with dual infection and 2 (1.61%) were
untypeable.
Prevalence of HCV mixed-genotype infections
Table 3 shows the prevalence of HCV mixed-genotype
infections determined by this system in different popula-
tions across Pakistan. Total 161 HCV isolates were found
having two genotypes. Of these 101 belonged to Punjab
region, 42 to N.W.F.P., 12 to Sindh region and 6 to Balo-
chistan region. More than half of the total HCV samples
with mixed infection were infected with HCV genotypes
3a and 3b (49.68%) followed by 3a + 1a (11.18%). The
overall rate of HCV mixed-genotype infections in patients
with chronic hepatitis C was 6.98%, which was signifi-
cantly lower than that in the thalassaemic patients (P <
0.001).
Possible risk factors for infection transmission in various 
genotypes
Various possible risk factors responsible for infection
transmission with each HCV genotypes are given in table
4. Over all the probable modes of transmission observed
were: 61.45% due to multiple use of needles/syringes;
10.62% due to major/minor surgery/dental procedures;
4.26% due to blood transfusion and blood products;
3.90% due to sharing razors during shaving or circumci-
sion by barbers, piercing instruments, nail clipers, tooth
brushes/Siwaks; in less than 1% due to needle stick, from
infected mother to baby and sexual transmission. For
20.35% subjects the mode of transmission was unclear as
no possible routes were observed at the time of survey and
they were still sporadic.
Discussion
Data so obtained from different parts of the world have
focused on the increasing interest of HCV genotyping by
mass screening as it is useful for the solution of epidemi-
Table 1: Frequency distribution of HCV genotypes and subtypes 
in the studied population (n = 3351)
HCV Genotype HCVγ Subtype No. of Isolates Percentage
1 1a 280 8.35
1b 101 03.01
1c 5 0.15
2 2a 252 07.52
2b 27 00.80
2c 3 00.09
3 3a 1644 49.05
3b 592 17.66
3c 25 0.75
4 4 50 01.49
5 5a 06 00.18
6 6a 04 00.12
Mixedα 161 04.80
Undeterminedβ 201 05.99
Total 3351 100
αMixed, two genotypes in one patients such as 3a+1a, 3a+3b etc.
βUndetermined, as the genotype assay was unable to assign type and 
these may be new subtypes.
γHCV, hepatitis C virus.
Table 2: Prevalence of HCV genotypes in different geographical regions of Pakistan (N = 3351).
Genotype Subtype Isolated from Punjab Isolated from NWFP Isolated from Sindh Isolated from Balochistan P value <
1 1a 172 (7.94%) 54 (6.56%) 22 (9.20%) 32 (25.80%) 0.01
1b 59 (2.72%) 21 (2.55%) 9 (3.76%) 12 (9.67%) 0.05
1c 04 (0.18%) 0 0 01 (0.80%) -
2 2a 140 (6.46%) 63 (7.65%) 23 (9.62%) 26 (20.96%) 0.01
2b 18 (0.69%) 7 (0.85%) 1 (0.41%) 1 (0.80%) -
2c 02 (0.09%) 01 (0.12%) 0 0 -
3 3a 1128 (52.10%) 397 (48.23%) 95 (39.74%) 24 (19.35%) 0.01
3b 358 (16.53%) 157 (19.07%) 63 26.35%) 14 11.29%) 0.01
3c 14 (0.64%) 07 (0.85%) 03 (1.25%) 01 (0.80%) -
4 4 25 (1.15%) 19 (2.30%) 1 (0.41%) 5 (4.03%) NS
5 5a 5 (0.23%) 1 (0.12%) 0 0 -
6 6a 1 (0.05%) 3 (0.36%) 0 0 -
Mixedα 101 (4.34%) 42 (5.10%) 12 (5.02%) 6 (4.83%) NS
Undeterminedβ 138 (6.37%) 51 (6.19%) 10 (4.18%) 02 (1.61%) NS
Total 2165 823 239 124 3351
αMixed, two genotypes in one patients such as 3a+1a, 3a+3b etc.
βUndetermined, as the genotype assay was unable to assign type and these may be new subtypes.BMC Infectious Diseases 2008, 8:69 http://www.biomedcentral.com/1471-2334/8/69
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ological questions and development of vaccines against
HCV. Furthermore it has been shown to be beneficial to
facilitate therapeutic decisions and strategies [25-27]. It
has been demonstrated that the severity of the disease, its
progression and response to therapy may vary according
to the genotype [10,28].
Substantial regional differences appear to exist in the dis-
tribution of HCV genotypes. Thus knowledge on the dis-
tribution of various genotypes in our country is essential
for its prognostic implications in chronic hepatitis C
infection. In the present study the frequency of various
genotypes of HCV present in Pakistan and various risks for
possible transmission were observed. All serum samples
tested were HCV-RNA positive by PCR and could thus be
genotyped. However, genotype-specific PCR products
were seen in about 94% serum samples by this molecular
biology-based system that is an excellent percent of the
sample size. The data of the present study correspond well
to previous studies, in which genotypes or serotypes were
determined from other regions of the world [29-31]. The
presence of various HCV genotypes such as 1a, 1b, 2a, 3a,
and 3b reported in this study have also been reported in
the earlier studies with predominated genotype 3 in Paki-
Table 4: Possible route of transmission of various HCV genotypes (N = 3351).
HCV Possible Mode of Transmission
HCV Subtype(N) Multiple use of needles/
syringes (%)
Major/minor surgery, 
dentil procedures (%)
Blood and blood 
products (%)
Sharing razors, piercing 
instruments, Nail clippers, 
tooth brushes (%)
Sporadic (%)
1a (280) 30 (10.71) 101 (36.07) 6 (2.14) 2 (0.71) 141 (50.35)
1b (101) 11 (10.89) 38 (37.62) 2 (1.98) 6 (5.94) 44 (43.56)
1c (05) - - 1 (20) 1 (20) 3 (60)
2a (252) 43 (17.06) 18 (7.14) 09 (3.57) 51 (20.23) 131 (51.98)
2b (27) 2 (7.4) 2 (7.4) 1 (3.7) 16 (59.25) 6 (22.22)
2c (03) - 1 (33.33) - 2 (66.66) -
3a (1644) 1421 (86.43) 88 (5.35) 13 (0.79) 12 (0.72) 110 (6.69)
3b (592) 427 (72.12) 43 (7.26) 5 (0.84) 2 (0.33) 115 (19.42)
3c (25) 3 (12) 5 (20) 3 (12) 9 (36) 5 (20)
4 (50) 11 (22) 19 (38) 13 (26) 1 (2) 6 (12)
5a (6) 5 (83.33) 1 (16.66) - - -
6a (4) 4 (100) - - - -
Mixed (161) 31 (19.25) 9 (5.59) 85 (52.79) 25 (15.52) 11 (6.83)
Undetermined (201) 51 (25.37) 31 (15.42) 5 (2.48) 4 (1.99) 110 (54.72)
Total 2039 (61.45) 356 (10.62) 143 (4.26) 131 (3.90) 682 (20.35)
αMixed, two genotypes in one patients such as 3a+1a, 3a+3b etc.
βUndetermined, as the genotype assay was unable to assign type and these may be new subtypes.
Table 3: Prevalence of HCV mixed genotypes in Pakistan (n = 161).
HCV isolate with Mixed 
genotypes
Isolated from Punjab Isolated from N.W.F.P Isolated from Sindh Isolated from Balochistan N
3a + 3b 56 16 4 4 80
3a + 1a 10 5 2 1 18
3a + 1b 5 4 0 1 10
3a +2a 5 2 2 0 09
1a + 1b 5 3 1 0 09
1a + 3b 4 2 1 0 07
3a + 1c 3 3 1 0 07
2a + 1b 4 1 0 0 05
3b + 2a 3 1 0 0 04
3a + 2b 2 1 0 0 03
1a + 4 0 2 1 0 03
3a + 4 1 1 0 0 02
2a + 1a 1 1 0 0 02
3a + 6a 1 0 0 0 01
Total 101 42 12 6 161
N.W.F.P, North West Frontier Province; HCV, hepatitis C virusBMC Infectious Diseases 2008, 8:69 http://www.biomedcentral.com/1471-2334/8/69
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stan [21,22]. Though these studies were done with lower
sample sizes, the reported genotypes frequencies are the
same as observed in the present study. Additionally six
more genotypes such as 1c, 2c, 3c, 4, 5a and 6a were iso-
lated for the first time ever from this country in the present
study. The frequency of genotype distribution in the
present study also seems to be quite similar to that
reported from other South Asian countries such as Nepal
[17] and India [32,33] where genotype 3 was found as the
predominant genotype but different from those in Japan
[34], Thailand [35], Vietnam, USA and Western Europe
[36] where genotype 1 is the most prevalent HCV geno-
type.
When the results of the present study on HCV genotypes
were compared to the genotyping results obtained in
other studies from Pakistan [21,22], it was observed that
the frequency of genotype 1 is increasing in this country
without any increase in the frequency of genotype 3. It
seems that in coming 15–20 years the current most prev-
alent genotype 3a will be replaced by less common geno-
type 1 (a or b). If this actually happens here in Pakistan, it
will complicate more the present situation of HCV that is
a big health problem in this country. Recently replace-
ment of one HCV genotype (type 1b) by another (type 2)
has been reported from Venezuela that took only 10 years
time for this displacement [36]. We also suggest confirm-
ing this observation by conducting other studies on HCV
genotypes. Another interesting finding of the study is the
isolation of genotype 4 for the first time from Pakistan
although this genotype is believed to be absent from Paki-
stan [22]. HCV genotype 4 is prevalent in the Middle East
and Central Africa; however, our patients did not have a
history of visit to these areas of the world. Genotype 4 has
been reported to be frequently associated with cirrhosis
and a poor response to interferon [37,38]. Like Pakistan,
HCV genotype 4 is also rare in the United Sates and there
are few published data regarding response to therapy in
patients with HCV genotype 4 infections in Pakistan and
United States [39]. None of the genotype 4 having patient
has history of visit to Middle-East.
In order to discern if there are any regional differences in
HCV genotype distribution in Pakistan, the distribution
for this population was examine by individual Provinces.
No regional difference with respect to HCV genotype dis-
tribution was seen in the Provinces of Punjab, N.W.F.P
and Sindh where the most prevalent genotype is 3a fol-
lowed by 3b. But a clear difference was observed in the
Province of Balochistan where the predominant genotype
found was 1a followed by 2a and 3a. Balochistan shares a
long boarder with Iran in the west where genotype 1 is the
predominant genotype in the region [40]. It is quite pos-
sible that genotype 1 may enter to Pakistan from Iran
through local persons who cross boarder for jobs and
trade. HCV genotypes distribution described in this study
does not present modification by gender, and the distri-
bution of HCV genotypes was similar both in male and
female HCV patients with no significant difference seen
for various genotypes in male and female patients (P <
0.05). The results of the present study indicate that HCV
genotype distribution varies with age. It has already been
reported that HCV genotype distribution varies with age
in both male and female patients [41]. Subtypes 1a and
1b were found most prevalent among older patients,
whereas subtype 2a/2b and 3a/3b were mainly found
among younger ones.
Some studies suggest that different types of HCV may be
associated with different transmission routes. In the
present study majority of the patients seem to have more
than one route of transmission however we took the most
probable one for data analysis. In Pakistan genotype 3a is
the most prevalent genotype and more than 86% patients
with genotype 3a received multiple injections. It is quite
possible that this type was spread in Pakistan by doctors,
vaccination teams and other medical persons using non-
disposable syringe before 1990 when one syringe was
used for injections to all attended patients. This type of
practice is still there in the rural areas of the country. This
observation is supported by a study where subtype 3a
appeared to be prevalent among injection drug users and
it is believed that it was introduced into North America
and the United Kingdom with the widespread use of her-
oin in the 1960s [42]. Further, it has also been reported
that HCV genotype 3a is particularly prevalent in intrave-
nous drug abusers in Europe and the United States [43].
For genotype 1a and 1b, the probable causes of transmis-
sion observed in the present study were major/minor sur-
geries and dental procedures. This is in agreement with a
study from Hungry where majority of the cases with gen-
otype 1 has a history of hospitalization for major/minor
surgery, dental procedures and shaving by barbers. In con-
trast in one study, 95% of all patients with genotype 1
were infected with subtype 1b and majority of those
patients had received transfusions of blood and/or blood
products [30]. Genotype 2a was more frequently seen
(>50%) in case with history of no apparent causes of
transmission. Mode of transmission was not clear for
more than half of patients with untypable genotypes.
Type 4 is uncommon in this country and its route of trans-
missions were surgeries (38%) followed by reuse of
syringes (22%). As expected, the prevalence of HCV
mixed-genotype infections was high (52.79%) in thalas-
saemic patients who had received multiple blood transfu-
sions.
It appears that more than 70% of the cases were acquired
in hospitals or other medical facilities because a large
number of subjects (61.45%) received therapeutic injec-BMC Infectious Diseases 2008, 8:69 http://www.biomedcentral.com/1471-2334/8/69
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tions and surgeries (10.62%) from the clinics of local gen-
eral practitioners in both government and private
hospitals. It has already been reported that Pakistan has
one of the highest frequencies of injections in the world
and the average number of injections per person per year
is more than 9 injections (44–45). Further been reported
in the same studies that 49% of patients receive injections
at their first outpatient visit where in addition to the
unnecessary use of injections, safe injection practices are
not followed. Furthermore, previous vaccination have
also been alleged to ignore safe injection practices that
was largely received at the public health-care facilities
including the use of used syringes [44,45]. As shown in
the present study and also reported in previous other stud-
ies [44,45] subjects who received more injections were
more likely to be infected with HCV and these non-sterile
syringes or needles may be the source of HCV infections.
According to a survey conducted by Ministry of Health, in
Pakistan more than 72% therapeutic injections and 50%
immunization injections in public health-care facilities
are unsafe and potentially dangerous [46]. In these studies
it is further shown that the use of multiple-dose vials is
common in many government and private sector hospi-
tals of Pakistan that is the major risk factor for the trans-
mission of HCV infection [44-46] especially genotype 3a.
Conclusion
The predominant HCV genotype in Pakistan is type 3a fol-
lowed by 3b and 1a. Six HCV genotypes such as 1c, 2c and
3c, 4, 5a and 6a were isolated for the first time from Paki-
stan during the study. The frequency of genotype 1 was
observed to be increasing in this country without any
increase in the frequency of genotype 3 that may be very
dangerous in coming 15–20 years. Regional difference in
genotypes was observed only in Balochistan province of
Pakistan. More than 70% of the cases in Pakistan are hos-
pitals acquired.
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